---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008452"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:48:39.822897+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nkarta reports FY2022 net loss of $113.8M; cash $354.9M; NKX101/019 updates in 2023

## Summary
- Net loss of $113.8M ($2.61 diluted EPS) for FY2022; Q4 loss $32.6M ($0.67).
- Cash and investments total $354.9M; management expects runway to fund operations into 2025.
- R&D expenses $90.9M (FY) and $26.8M (Q4); G&A $28.1M (FY) and $8.1M (Q4).
- NKX101: 60% CR in AML at higher doses; additional data expected H1 2023.
- NKX019: 70% CR in B-cell malignancies; dose expansion enrolling; updated data expected in 2023.

## SEC filing metadata
- accession: 0000950170-23-008452
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017023008452/0000950170-23-008452-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017023008452/nktx-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008452
- JSON: https://secwatch.observer/filing/0000950170-23-008452.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008452.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.